[MID-TERM RESULTS OF ARTERIOVENOUS AXILLARY LOOP GRAFT ON CHEST FOR ESTABLISHING HEMODIALYSIS ACCESS].

Jie Yin,Kang She,Xiansheng Zhang,Hongjie Guo,Gong Cheng
DOI: https://doi.org/10.7507/1002-1892.20150245
2015-01-01
Abstract:OBJECTIVE:To explore the role of arteriovenous axillary loop graft (AVALG) on chest for establishing hemodialysis access in patients with chronic renal failure.METHODS:A retrospective analysis was made on the clinical data of 12 patients with chronic renal failure who underwent an AVALG on chest for hemodialysis access between December 2010 and May 2014. There were 2 males and 10 females with an average age of 65.25 years (range, 46-75 years). The main causes were chronic glomerulonephritis in 6 cases, diabetic nephropathy in 4 cases, and both kidney resection because of urinary tract tumors in 2 cases. The disease duration was 2-12 years (mean, 6 years). The 12 patients all underwent 5-14 times (mean, 7 times) failed prior vascular accesses [arteriovenous fistula (AVF) and arteriovenous graft (AVG)] leading to exhaustion of venous access sites on the upper extremities.RESULTS:The AVALG on chest were functionally useful for hemodialysis access, 2-3 times per week, and the blood flow was 250-350 mL/minute; the average time for the first dialysis was 48 days (range, 42-93 days). All patients were followed up 12-54 months (mean, 20.92 months). There was no death during perioperative period. The primary patency rates at 6 and 12 months were 91.7% and 83.3% respectively, and the secondary patency rates at 6 and 12 months were both 100%. After operation, infection (1 case), thrombosis (2 cases), bleeding (2 cases), and swollen (1 case) occurred, which were all cured after corresponding treatment.CONCLUSION:AVALG on chest is a supplementary option for chronic renal failure patients with inadequate upper extremity venous access sites after repeat occlusion.
What problem does this paper attempt to address?